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Palo Alto, CA, USAA B S T R A C TBackground: HER2 positive (HER2þ) metastatic breast cancer (MBC) is
associated with high mortality. Trastuzumab was approved for use in
1998, but the life-years saved from ﬁrst-line use are unknown, as are
the potential US population beneﬁts from adding pertuzumab. Objec-
tives: The ﬁrst aim was to estimate the number of life-years saved by
using ﬁrst-line trastuzumab between 1999 and 2013 in HER2þ women
with MBC. In addition, based on these estimates, the second aim was
to project the life-years that could be saved by adding pertuzumab to
trastuzumab in ﬁrst-line therapy. Methods: We constructed a simu-
lation model accounting for incidence, testing rates, therapy utiliza-
tion, and overall survival. The model was run for 1999 to 2013 (15
years) to estimate the life-years saved from using trastuzumab plus
chemotherapy instead of chemotherapy alone. The model was also
run from 2013 to 2027 (15 years) to project the life-years that might be
saved by adding pertuzumab. Uncertainty was incorporated using
Monte-Carlo methods. Results: The estimated number of women
with HER2þ MBC varied over time, with the peak of 9700 in 2005ee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.06.003
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ndence to: Mark D. Danese, 2801 Townsgate Road,and the low of 7700 in 2018. The cumulative incremental life-years
saved because of ﬁrst-line trastuzumab use from 1999 to 2013 was
estimated to be 156,413 (95% simulation interval 114,840–195,201). The
projection for pertuzumab from 2013 to 2027 was 137,959 (95%
simulation interval 56,011–225,069). Exploratory analyses of value
showed that pertuzumab, trastuzumab, and chemotherapy is asso-
ciated with a $1.10 billion gain compared with chemotherapy alone,
and adding pertuzumab is associated with a $0.06 billion gain
compared with trastuzumab with chemotherapy. Conclusions: This
simulation model suggests that substantial progress has been made
in treating HER2þ women over the past 15 years, and the future may
witness similar gains with the introduction of pertuzumab.
Keywords: breast cancer, epidemiology, life-years, pertuzumab,
trastuzumab.
& 2015 Published by Elsevier Inc. on behalf of International Society for
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There are more than 100,000 women with metastatic breast
cancer in the population at any point in time [1,2]. Metastatic
breast cancer is associated with high mortality, particularly in the
20% to 25% of women whose tumors express human epidermal
growth factor receptor 2 (HER2) [3,4]. Without targeted therapy,
median survival is less than 2 years [5,6]. Therefore, therapies
that improve overall survival represent important advances.
Trastuzumab signiﬁcantly changed the prognosis for HER2
positive (HER2þ) women. The initial randomized, placebo-
controlled trial included women with 2þ immunohistochemistry
(IHC) results, a subgroup with a lower response rate [7]. The
trial also had 67% of patients cross over to trastuzumab
after progression. Despite these dilutive effects, randomizationto trastuzumab was associated with a 20% reduction in all-cause
mortality (25.1 vs. 20.3 month median time to death). Later
studies have suggested that the prognosis for HER2þ women
treated with trastuzumab is as good as, or better than, the
prognosis for women with non-HER2þ disease treated with
chemotherapy [8,9].
The improvements in overall survival are not limited to
trastuzumab. Targeting a separate HER2-binding site and provid-
ing a more complete blockade of HER2 signaling, pertuzumab was
recently approved for use in conjunction with trastuzumab plus
chemotherapy. In the CLEOPATRA study [10,11], ﬁrst-line therapy
with the combination of both HER2-targeted therapies resulted in
a 34% reduction in the risk of all-cause mortality compared with
trastuzumab plus chemotherapy alone. Recently ﬁnalized overall
survival data showed a signiﬁcant difference of 15.7 months (40.8on behalf of International Society for Pharmacoeconomics and
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 7 6 – 8 8 3 877vs. 56.5 months) in median survival [12]. This represents a
signiﬁcant potential for increased years of life in the HER2þ
metastatic breast cancer population, as has been suggested by
others for trastuzumab [13].
As with any new therapy, the population-level beneﬁts of
HER2-targeted therapy reﬂect the adoption patterns in clinical
practice. The life-years gained in the population are not only a
function of relative risk reductions but also the number of
women, how readily they are identiﬁed in clinical practice, and
their expected (average, not median) survival. Further complicat-
ing population-level inferences are improvements in HER2 test-
ing and the introduction of trastuzumab in the adjuvant setting.
Accordingly, there were two aims for this research. The ﬁrst
aim was to account for these temporal trends and to estimate the
number of life-years saved by using ﬁrst-line trastuzumab
between 1999 and 2013 in HER2þ women with metastatic breast
cancer. In addition, based on these estimates, the second aim
was to project the life-years that could be saved by adding
pertuzumab to trastuzumab in ﬁrst-line therapy.Methods
We constructed a model to estimate the life-years saved by
using trastuzumab as ﬁrst-line therapy in HER2þ metastatic
breast cancer, compared with a counterfactual scenario in
which trastuzumab did not exist. The model was constructed
in Microsoft Excel 2010, with the calculations organized by
sections as described below (Fig. 1). The Epidemiology section
estimates the number of HER2þ women with either de novo or
recurrent stage IV (metastatic) breast cancer in each year of the
model. The Utilization section estimates the proportion of
HER2þ women who received therapy in each year of the model.
The Survival section estimates the expected life-years lived for
women receiving ﬁrst-line therapy. These sections are com-
bined to estimate survival for cohorts of women receiving
trastuzumab plus chemotherapy or receiving chemotherapy
alone between 1999 and 2013; they can also project results for
pertuzumab and trastuzumab plus chemotherapy and for tras-
tuzumab plus chemotherapy for women between 2013 and 2027.Fig. 1 – Overview of the model. Note: Model ﬂow is the same for p
the comparison is pertuzumab plus trastuzumab plus chemothe
and trastuzumab utilization for 2013 are assumed to be unchan
epidermal growth factor receptor 2; PR, progesterone receptor; S
version of ﬁgure is available online.)See Appendix Tables 1 and 2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.06.003 for a summary of
model inputs, which are described in more detail below.
Epidemiology
Breast cancer incidence
The incidence of stage I to III breast cancer in US women was
based on 2006 to 2008 Surveillance, Epidemiology and End Results
(SEER) data using age-speciﬁc rates for each single year of age (0–
100) from 18 available registries [14]. The rates were stratiﬁed by
estrogen receptor (ER) status, progesterone receptor (PR) status,
and nodal involvement (0 nodes vs.Z1 nodes). Women who were
diagnosed at autopsy were excluded. We assumed that patients
with missing ER, PR, or nodal status would not be HER2 tested
and are excluded from our rate estimates (11% of women in the
SEER registries in our base years).
The use of a base period from 2006 to 2008 allowed for the
incorporation of temporal changes in incidence rates based on a
study by Anderson et al. [15]. This study derived ER-speciﬁc
incidence rates, accounting for temporal trends in missing ER
status over time (26% in 1992, declining to 5% in 2008) [15,16].
This study also provided average annual percent increase esti-
mates for future years for ER-positive and ER-negative cancers.
HER2 status and population counts
Because HER2 status is not available over the time frame of our
study in SEER, the number of HER2þ patients was estimated as a
proportion of the total breast cancer population within each of
the four mutually exclusive strata deﬁned by ER and PR status.
This was done by applying estimates of the association between
HER2 status and both ER and PR status based on published
population-based data from the California Cancer Registry. The
estimates for stage I to III cancer were taken from Parise et al. [17]
and adjusted for age group and nodal status based on marginal
estimates available from other publications using the California
Cancer Registry [17–19]. The resulting incidence rates were
combined into hormone positive and hormone negative and
compared with those published by Clarke et al. [18] and found
to provide a qualitatively similar curvilinear relationship betweenertuzumab, except that the time interval is 2013 to 2027 and
rapy versus trastuzumab plus chemotherapy. HER2 testing
ged through 2027. ER, estrogen receptor; HER2þ, human
EER, Surveillance, Epidemiology and End Results. (Color
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Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.003).
Because of differences in populations, a more precise comparison
was not possible. Rates for de novo metastatic disease were
derived from Parise et al. [17] with no adjustment for age (due to
lack of data).
The resulting incidence rates for each year were multiplied by
the US Census–based female population counts for each year to
estimate the number of HER2þ breast cancer cases in each year
[20]. ER and PR status were combined into hormone receptor (HR)
negative (both ER- and PR-negative) and positive (ER- or PR-
positive) status. This resulted in four cohorts deﬁned by HR and
nodal status for each calendar year of diagnosis, each of which
was followed in the simulation for 15 years to identify recurrent
women and the year of the recurrence. Recurrences outside of
the model time horizon were not included.
Recurrence and timing
The BCIRG 006 trial of adjuvant trastuzumab in women with
node-positive and high-risk node-negative HER2þ breast cancer
was used for estimating recurrence rates stratiﬁed by nodal
status (0 vs. Z1) [21,22]. Recurrence rates were applied to the
patients estimated from SEER incidence rates. Women were
removed from risk of recurrence when they had any of the
following events based on the BCIRG 006 disease-free survival
rates: local recurrence, distant recurrence, contralateral tumor,
and death [21]. Only distant recurrence was considered for
subsequent ﬁrst-line treatment, and women were censored when
the other events occurred. The recurrence rate varied with time
through year 4 based on analysis of slopes of the published
Kaplan-Meier curves; starting in year 5, the recurrence rate was
assumed to be constant until year 15, and then was 0 afterward
[21].
Beginning in 2006, the model incorporated the treatment of
women with stage I to III HER2þ breast cancer with trastuzumab
[23–25]. The proportion treated was assumed to be a constant rate
of 71% based on the utilization patterns described for metastatic
disease (see the Utilization section). Trastuzumab efﬁcacy was
based on the BCIRG 006 study. The relative risk of recurrence with
trastuzumab was constant across subgroups of age and HR
status, but varied by nodal status based on published, stratiﬁed
estimates [21]. Women who were treated with adjuvant trastu-
zumab were treated again with trastuzumab at the time of
metastases.
Using this recurrence data, each cohort of women diagnosed
with stage I to III cancer from 1985 to 2027 was tracked for 15
years to identify deaths and recurrences in subsequent calendar
years in the simulation. All recurrences within a calendar year
were combined. Women diagnosed with de novo stage IV cancer
were included in the calendar year of their stage IV diagnosis.
HRþ and HR– women were combined to align with the survival
results. The end result was a set of patient counts, by age, of
women who developed HER2þ metastatic breast cancer in each
calendar year from 1999 to 2027.
Utilization of Trastuzumab and Pertuzumab
Utilization was estimated on the basis of three components:
HER2 testing rates, utilization rates of targeted therapy, and
market share of trastuzumab. Estimates were applied to the
years indicated in each study, and extended to later years in
the absence of additional estimates for those years (i.e., estimates
were carried forward in time, as necessary). HER2 testing rates
were based on reported results from US cancer registry data
[18,26–28]. Targeted therapy utilization rates were based on
observational data for HER2þ patients younger than 85 years,
with lower utilization for women older than 85 years based onchemotherapy use in the oldest patients [29–31]. Because we
could ﬁnd no reliable published data, we included an assumption
that the market share of trastuzumab for ﬁrst-line use changed
from 100% to 95% in 2007 after the introduction of lapatinib.
For the pertuzumab time interval (2013–2027), we assumed
that the 2013 utilization estimates would be unchanged through
2027. To estimate the potential life-years that might be saved, we
set the pertuzumab utilization to be 100%.
Some women with ER- and/or PR-positive tumors may be
treated initially with hormone therapy; however, we did not
address the use of hormone therapy in this model because most
of these women will receive chemotherapy, and because the
model incorporates the likelihood of receiving targeted therapy.
Overall Survival
Estimates of individual patient data were extracted from Kaplan-
Meier curves [32] in seven published trials of ﬁrst-line trastuzu-
mab þ chemotherapy or chemotherapy alone (see Appendix
Table 3 in Supplementary Materials found at http://dx.doi.org/
10.1016/j.jval.2015.06.003) [5,6,11,33–36]. Potentially relevant trials
were identiﬁed on the basis of studies identiﬁed in published
reviews and meta-analyses [37–40] and were selected if they met
the following additional inclusion criteria: 1) HER2þ deﬁned as
IHC 3þ or ﬂuorescence in situ hybridization positive; 2) the trial
did not allow cross over to trastuzumab after progression in
untreated women; 3) the trial included both HRþ and HR–
patients; and 4) the trial provided a Kaplan-Meier estimate of
overall survival. Observational studies were not included.
The hazard functions (the rate of death over time) for chemo-
therapy alone and trastuzumab plus chemotherapy were
estimated by pooling data across studies. Results were pooled using
spline-based Royston-Parmar proportional-odds survival models in
Stata 12.1 [41] (see Appendix Fig. 2 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.06.003). Proportional-
odds models resulted in an improved Akaike information criterion
compared with proportional-hazards models. Heterogeneity was
not assessed. Results were incorporated into the model as monthly
hazard rates, which were converted to probabilities. The effect of
pertuzumab was incorporated as the reported hazard ratio from the
most recent update of the CLEOPATRA trial multiplied by the
predicted hazard rate for trastuzumab plus chemotherapy [11].
Because virtually all the trial populations were younger than
75 years, we adjusted survival for patients older than 75 years to
account for higher noncancer mortality [42]. The life-years
estimated in the model were accrued only for the proportion of
women expected to be truly HER2þ in community-based testing
(86% through 2006 and 90% after the introduction of testing
recommendations in 2007) [43–45]. Therefore, the model does
not include women with false-positive HER2þ tumors.
Analyses
All inputs were incorporated as distributions reﬂecting the
uncertainty in their estimates, and the results were estimated
stochastically. Expected survival was estimated as the area under
the survival curve and was multiplied by the number of women
to estimate the life-years lived. The life-years gained was esti-
mated as the difference in life-years lived for each treatment, and
this difference was cumulated across the time interval of the
analysis. The calendar years of the analyses were 1999 to 2013 for
trastuzumab and chemotherapy alone (vs. chemotherapy alone)
and 2013 to 2027 for pertuzumab, trastuzumab, and chemo-
therapy (vs. trastuzumab and chemotherapy).
A scenario analysis was included in which all inputs were
optimized to reﬂect the best possible utilization uptake from the
beginning of the model. Within each iteration, uncertainty was
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Fig. 2 – Estimated overall survival by study and treatment
group from pooled trial data. Note: Results are reported by
study, and results are pooled across arms that reported
multiple arms with the same treatment. Dotted lines reﬂect
chemotherapy alone, and solid lines reﬂect trastuzumab plus
chemotherapy. Results for the pertuzumab arm of Swain
et al. are available in the original publication and are not
shown in this ﬁgure to enhance readability. Details of each
study are provided in Appendix Table 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.003.
(Color version of ﬁgure is available online.)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 7 6 – 8 8 3 879included by running 2000 iterations of the model, with each input
sampled from its own distribution. Relative risks and hazard rates
were sampled using lognormal distributions, rates were sampled
using normal distributions, and proportions were sampled using
beta distributions. When standard errors were not available, we
estimated approximate standard errors on the basis of the sample
size of the study used for the estimate.
Value of life-years saved
We explored an example calculation of the value of trastuzumab
and the combination of trastuzumab and pertuzumab at a pop-
ulation level by applying an economic value to each life-year saved
and comparing this to the cost of therapy. No distributions or
sampling was incorporated into these exploratory analyses. The
economic calculations were estimated in 2015 dollars using the
results for women diagnosed in the 2013 calendar year. This
cohort was selected because it is the only year that the models
overlap and provide results for all three regimens: chemotherapy
alone; trastuzumab and chemotherapy; and pertuzumab, trastu-
zumab, and chemotherapy. Also, in the model, utilization does not
change after 2013, making all years after 2013 very similar in terms
of counts of women and life-years saved. Also, addressing costs of
earlier years involving only trastuzumab would require a detailed
accounting of changes in pricing and patterns of care over time.
The value of $150,000 per life-year saved was used on the basis
of work by Yabroff et al. [46] for multiple solid tumors, which was
based on willingness-to-pay estimates in the literature [47]. The
cost of trastuzumab was estimated using 2015 Medicare average
selling price reimbursement rates for both trastuzumab ($3716 per
440-mg vial) and pertuzumab ($4292 per 420-mg vial). Because both
drugs are used until progression, we estimated mean progression-
free survival from the CLEOPATRA study using Royston-Parmar
models as described above, with two degrees of freedom and
hazard parameterization. Loading doses for trastuzumab and per-
tuzumab were included as part of the cost estimates. A single vial
every 3 weeks was used for both therapies, assuming an average
weight of 70 kg. Cost offsets and costs of adverse events were not
included, nor were the costs of administration or of any additional
chemotherapy agents (e.g., docetaxel). Discounting was not applied,
and adherence was considered to be 100%.Results
The pooled survival data were based on four study arms for
chemotherapy alone (n ¼ 133), and eight study arms for trastu-
zumab plus chemotherapy (n ¼ 928), reﬂecting 1061 individuals,
550 deaths, and 29,284 person-months of follow-up (Fig. 2). The
median survival for chemotherapy alone was 16 months, com-
pared with 36 months for trastuzumab plus chemotherapy. In the
model, the mean (not median) overall survival for women receiv-
ing chemotherapy alone was estimated to be 25.5 months for
women younger than 75 years and 16.1 months for women older
than 75 years. For trastuzumab with chemotherapy, the estimates
were 52.0 and 35.2 months. For pertuzumab with trastuzumab
and chemotherapy, the estimates were 73.7 and 50.7 months.
The number of women with metastatic HER2þ disease over
the 1999 to 2013 time interval was 138,778. It varied over time,
with the peak of 9692 in 2005 and the low of 8801 in 2017. Because
of the projected variations in breast cancer over time, the total
number of cases increased after 2017, with a projected total of
9657 by 2027. Overall, the model estimated that 60% of all
possible patients were treated over the interval from 1999 to
2027. For those younger than 75 years, the proportion was 67%,
but for those older than 75 years it was 31%. The total number of
trastuzumab-treated women with metastatic breast cancer from
1999 to 2013 is given in Figure 3, and a more detailed table by agegroup and year (Appendix Table 4) is available in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.003.
During the period from 1999 to 2013, the number of life-years
lived for HER2þ women with metastatic breast cancer treated
with trastuzumab was 306,175 (95% simulation interval 275,063–
338,203), and the individual year estimates ranged from a low of
7545 in 1999 to a high of 23,759 in 2005. In comparison, if these
women had not received trastuzumab, the model estimates that
they would have lived 149,762 years (95% simulation interval
122,499–180,391), ranging from 3688 in 1999 to 11,619 in 2005. The
cumulative incremental life-years saved because of ﬁrst-line
trastuzumab use from 1999 to 2013 were estimated to be
156,413 (95% simulation interval 114,840–195,201; Fig. 4; see
Appendix Table 5 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2015.06.003).
We conducted a scenario analysis by assuming 100% utiliza-
tion of trastuzumab from 1999 to 2013, and assuming optimal
HER2 testing (i.e., no false positives or negatives) to estimate the
potential life-years that could have been saved under the
assumption of optimal identiﬁcation of patients. In this scenario,
the cumulative incremental life-years saved was 281,948 (95%
simulation interval 209,304–350,850).
During the period from 2013 to 2027, the number of life-years
lived in HER2þwomen with metastatic breast cancer treated with
trastuzumab was projected to be 328,200 (95% simulation interval
292,158–365,342), and the individual year estimates ranged from a
low of 20,071 in 2018 to a high of 20,645 in 2027. In comparison, if
these women were to receive pertuzumab in addition, the model
estimates that they would live 466,159 years (95% simulation
interval 376,675–562,112), ranging from 28,477 in 2018 to 29,291 in
2027. The projection for the cumulative incremental life-years
saved with the addition of pertuzumab in all trastuzumab-
treated women from 2013 to 2027 was 137,959 (95% simulation
interval 56,011–225,069; Fig. 5; see Appendix Table 6 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.06.003). Simulations assuming less than 100% utilization of
pertuzumab yielded results proportional to the utilization
Fig. 3 – Estimated number of ﬁrst-line trastuzumab-treated HER2þ women with metastatic breast cancer (1999–2013). Note:
The estimated count of women with HER2þ metastatic breast cancer treated with trastuzumab is extended through 2027 for
the pertuzumab model. There are slight variations due to temporal trends in incidence, but the counts are similar to 2013. See
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.003 for the ﬁgure for 2013 through 2027. (Color
version of ﬁgure is available online.)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 7 6 – 8 8 3880(i.e., 50% utilization resulted in cumulative incremental life-years
saved that were half of the 100% utilization estimates). See Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.003
for underlying hazard functions and detailed results by year.
In terms of the exploratory economic value, we estimated that
an estimated 5161 women would be diagnosed in 2013 and
treated with trastuzumab, resulting in 11,059 life-years saved by
using trastuzumab with chemotherapy compared with chemo-
therapy alone. These life-years saved would result in $1.66 billion
of incremental value, and the additional 9100 life-years saved by
adding pertuzumab would represent $1.37 billion of incremental
value. Combined, the value of life-years saved for trastuzumab,
pertuzumab, and chemotherapy compared with chemotherapy
alone would be $3.03 billion in 2015 dollars.
On the basis of extrapolation of the CLEOPATRA trial data, we
estimated the mean time to progression to be 20.9 months in the
trastuzumab arm and 30.8 months in the pertuzumab, trastuzu-
mab, and chemotherapy arm. This results in an incremental cost
for treating the 5161 women of $0.62 billion if treated using
trastuzumab with chemotherapy for 20.9 months and $1.31Fig. 4 – Cumulative incremental life-years saved with trastuzum
model estimates the life-years lived for women treated with tra
years that might have been lived if they had received chemothe
cumulative life-years lived for each treatment approach from 19billion if treated with pertuzumab, trastuzumab, and chemo-
therapy for 30.8 months. Compared with chemotherapy alone,
the net gain for society would be $1.04 billion from adding
trastuzumab and $1.10 billion from adding both trastuzumab
and pertuzumab. Pertuzumab, trastuzumab, and chemotherapy
versus trastuzumab with chemotherapy resulted in an incremen-
tal gain of $0.06 billion (see Appendix Table 7 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.003).Discussion
According to our model, more than 150,000 life-years have been
accrued by women with HER2þmetastatic breast cancer because
of ﬁrst-line use of trastuzumab over the last 15 years. Over the
next 15 years, this total could be increased by another 137,000
additional life-years if pertuzumab were used in all women
projected to receive trastuzumab with chemotherapy. This
assumes no changes in the utilization of trastuzumab or in
survival after trastuzumab treatment. In short, the survival gainsab between 1999 and 2013. Note: In each calendar year, the
stuzumab plus chemotherapy, as well as the expected life-
rapy alone instead. The ﬁgure shows the difference in the
99 through 2013. (Color version of ﬁgure is available online.)
Fig. 5 – Cumulative incremental life-years saved with pertuzumab between 2013 and 2027. Note: In each calendar year, the
model projects the life-years lived for women treated with trastuzumab plus chemotherapy, as well as the expected life-years
that might be lived if all women were to receive pertuzumab in addition. The ﬁgure shows the difference in the cumulative
life-years lived for each treatment approach from 2013 through 2027. (Color version of ﬁgure is available online.)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 7 6 – 8 8 3 881from targeted therapy may be substantial, despite conservative
assumptions and a relatively small patient population.
Although this study has focused on value in terms of life-
years, other studies have incorporated other outcomes and
deserve discussion. The cost-effectiveness of trastuzumab in
metastatic breast cancer in the United States has been estimated
at $125,000 per quality-adjusted life-year (QALY) [48], and there
are various other evaluations that have generated varying results
[49]. Garrison and Veenstra [13] estimated the cost per QALY as
$86,000 as part of the ﬁrst population-level view of the value of
trastuzumab. They synthesized published economic models in
both metastatic and stage I to III breast cancer and estimated the
cost-effectiveness of the entire lifecycle of trastuzumab treat-
ment in the US population. Across both indications for use, they
projected that trastuzumab would be used in 319,000 women
from 1998 to 2016, would cost $15.4 billion in 1998 dollars, and
would save 432,547 QALYs for an overall incremental cost-
effectiveness ratio of $35,590 per QALY.
Although our model focuses mostly on treatment beneﬁts in
terms of life-years saved, it is important to understand the cost to
achieve those gains. Based on current prices, the expected
number of HER2þ women with metastatic breast cancer, and
the most current survival data, there is a net economic gain for
society from using trastuzumab and the addition of pertuzumab
slightly increases this gain. Whether $150,000 per life-year saved
is appropriate is an ongoing debate [47]. Some may prefer to use a
different threshold, or to use a cost per QALY.
Regardless of how the outcomes are measured, this model
shows that there is an adoption process and an evolution of care
that drives the magnitude of beneﬁt to society over time. The life-
years saved from trastuzumab were affected by improvements in
HER2-testing rates, increases in the utilization of trastuzumab,
and the introduction of therapy into the stage I to III HER2þ
breast cancer. The ﬁrst two yielded increases in life-years saved,
but the latter yielded a decrease due to improved disease-free
survival in early breast cancer. It is interesting to note that
282,000 life-years might have been saved under the unrealistic
assumption that all patients could be identiﬁed and treated. This
result highlights the importance of all aspects of clinical manage-
ment from diagnosis through treatment, something that is
particularly important for targeted therapies.
It is also interesting to estimate the approximate number of
HER2þ women with metastatic breast cancer in the United
States. The model peak was 9700 in 2005 and is projected todecline to 8801 by 2017, primarily because of effective treatment
in the adjuvant setting. After 2017, however, the model projects a
subsequent increase to 9657 by 2027 because of increases in
ER-positive cancer as projected by Anderson et al. [15] (based
on an improved statistical modeling approach to account for
missing data).
One of the strengths of these analyses is the incorporation of
distributions for all model inputs. This provides a plausible range
of results that are consistent with the inputs we used. In general,
we tried to make our estimates as accurate as possible. When
faced with making assumptions, we attempted to err on the
conservative side (i.e., biased toward fewer life-years saved, as
with incorporating ﬁrst-line utilization of lapatinib or by limiting
to a 15-year time horizon for recurrences).
There are limitations to models constructed from disparate
information sources. We do not have nationally representative
HER2þ incidence rates in the United States over our study time
frame; however, the similarity of our results and those from the
study by Clarke et al. [18] is reassuring. Because of our desire to
account for node-positive and node-negative patients separately,
we could not use the Clarke et al. [18] data directly. Simpler
models, however, could certainly be derived from the Clarke et al.
[18] data, from speciﬁc analyses directly from the California
Cancer Registry or other registries in which HER2 testing results
are available, or from the recently released data for the period
2010 to 2011 from the SEER program [50]. Also, we limited
recurrence to a 15-year window because of a lack of longer-
term data. This may lead to a slight underestimate of recur-
rences, and therefore, life-years saved.
Survival results are challenging to estimate for women with
HER2þ disease who receive chemotherapy alone. Both the early
trastuzumab trials in metastatic breast cancer included IHC 2þ
women without ﬂuorescence in situ hybridization conﬁrmation
and allowed more than 50% of women to cross over to trastuzu-
mab after disease progression [7,51]. Including IHC 2þ women
without ﬂuorescence in situ hybridization conﬁrmation would
tend to reduce estimates of overall survival, and cross-over would
tend to reduce differences between treatment groups. Our esti-
mate of a median survival of 16 months in untreated HER2þ
women is comparable, however, to the subset of women who did
not cross over in the study by Marty et al. [51]. Also, our 20-month
estimate for the difference in median survival between trastuzu-
mab plus chemotherapy and chemotherapy alone is comparable
to the estimate of 16.2 months (95% conﬁdence interval [CI] 7.4–
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 7 6 – 8 8 388225.1 months) in the meta-analysis by Kiely et al. [37]. This meta-
analysis used a reference group of HER2-negative women treated
with chemotherapy, who would be expected to have better
survival than HER2-positive women [4].
It is also instructive to consider estimates from observational
data. Comparison of overall survival from our pooled data to
observational results for HER2þ patients not treated with trastu-
zumab by Dawood et al. [8] shows good concordance. Estimated
12-month survival was 70.2% (95% CI 60.3–78.1) compared with
65% for our model, and 60-month survival was 13.2% (95% CI 5.9–
23.4) compared with 8% in our model. Kaufman et al. [29] report a
median survival of 25.9 months (95% CI 19.8–31.4) compared with
16.5 months for our model. According to the authors, however,
there was a potential bias toward enrolling patients with better
prognosis in the cohort [29].
The efﬁcacy of trastuzumab treatment might have increased
over time because of improvements in diagnosis and manage-
ment. Modeling of time-varying survival effects was beyond the
scope of our data inputs. Analyses in older patients receiving
trastuzumab, however, did not show any notable effects of
calendar year between 2000 and 2006, suggesting that temporal
effects may be small in the time frame of the trastuzumab
analyses that extend through 2013 [42]. With new therapies for
HER2þ disease in neoadjuvant, adjuvant, and metastatic settings,
as well as additional therapies on the way, these temporal trends
in efﬁcacy may become more important to understand.
Despite the limitations inherent in any simulation, our model
indicates the substantial progress that has been made in treating
HER2þ women over the past 15 years. And the results suggest
that the next 15 years may witness similar gains. To maximize
the effects of therapy, however, there is room to improve testing
as well as access to targeted therapy. The two aspects of care will
work synergistically with the survival advantages conferred by
existing, newly available, and future treatments.Supplementary Materials
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